Cargando…
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men globally. Despite improvements in the diagnosis and treatment of PCa, a significant proportion of patients with high-risk localized disease and all patients with advanced disease at diagnosis will experience pr...
Autores principales: | Yehya, Amani, Ghamlouche, Fatima, Zahwe, Amin, Zeid, Yousef, Wakimian, Kevork, Mukherji, Deborah, Abou-Kheir, Wassim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511807/ https://www.ncbi.nlm.nih.gov/pubmed/36176747 http://dx.doi.org/10.20517/cdr.2022.15 |
Ejemplares similares
-
MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer
por: Ghamlouche, Fatima, et al.
Publicado: (2023) -
Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional in vitro models
por: Monzer, Alissar, et al.
Publicado: (2022) -
Tissue-specific cancer stem/progenitor cells: Therapeutic implications
por: Yehya, Amani, et al.
Publicado: (2023) -
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014) -
Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)